Advertisement

International Journal of Clinical Pharmacy

, Volume 34, Issue 2, pp 290–294 | Cite as

Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study

  • Lucas MagedanzEmail author
  • Erci Maria Silliprandi
  • Rodrigo Pires dos Santos
Short Research Report

Abstract

Background Antimicrobial stewardship programs (ASP) have been implemented to promote rational use of antimicrobial drugs. Multidisciplinary teams are needed to form effective committees. Objective Assess the impact of ASP, with and without the presence of a pharmacist, in a cardiology hospital in Brazil. Methods The program started with an infectious disease (ID) physician, and after 22 months, a pharmacist started to work in the ASP team. We present data related to: stage 1—before the program implementation; stage 2—with the ID physician; and stage 3 with the inclusion of a pharmacist. Analysis was made by segmented regression of time series. Results After the start of ASP there was a significant reduction of consumption of all antimicrobials. The pharmacist contributed to the significant reduction in consumption of fluoroquinolones, clindamycin and ampicillin/sulbactam and in increase in total cephalosporins use in stage 3. Adherence rate to the ASP team recommendations was 64.1%. There was a significant reduction of 69% in hospital antibiotics costs. Conclusion A non-expensive ASP in a limited resource country resulted in reductions in antimicrobial consumption and costs. The multidisciplinary team contributed to maximize the impact of interventions.

Keywords

Antibiotics Antimicrobial stewardship program Brazil Infection control pharmacist Pharmacopidemiology 

Notes

Acknowledgments

We would like to thank the Instituto de Cardiologia—Fundação Universitária de Cardiologia, for their administrative support, and to Anderlise Luvizetto, Juliana Guedes, Otávio Fontoura Carvalho and Thalita Jacoby for their contribution to this study.

Funding

None.

Conflicts of interest

The authors declare no conflicts of interests with regard to the material published in this article.

References

  1. 1.
    Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008;47(Suppl 1):S3–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Infectious Diseases Society of America; Society for Healthcare Epidemiology of America, et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRefGoogle Scholar
  3. 3.
    Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998;17:20–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis. 2007;44:867–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24:699–706.PubMedCrossRefGoogle Scholar
  6. 6.
    Solomon DH, Van Houten L, Glynn RJ, Baden L, Curtis K, Schrager H, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001;161:1897–902.PubMedCrossRefGoogle Scholar
  7. 7.
    Pakyz AL, Oinonen M, Polk RE. Relationship of Carbapenem restriction in 22 University teaching hospitals to Carbapenem use and Carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:1983–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Burke JP. Antibiotic resistance—squeezing the balloon? JAMA. 1998;280:1270–1.PubMedCrossRefGoogle Scholar
  9. 9.
    Paterson DL. “Collateral damage” from cephalosporin or fluoroquinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341–5.PubMedCrossRefGoogle Scholar
  10. 10.
    MacKenzie FM, Gould IM, Bruce J, Mollison J, Monnet DL, Krcmery V, et al. The role of microbiology and pharmacy departments in the stewardship of antibiotic prescribing in European hospitals. J Hosp Infect. 2007;65(Suppl 2):73–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001;33:289–95.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Lucas Magedanz
    • 1
    Email author
  • Erci Maria Silliprandi
    • 1
  • Rodrigo Pires dos Santos
    • 1
    • 2
    • 3
  1. 1.Hospital Infection Control Service, Instituto de Cardiologia FundaçãoUniversitária de Cardiologia de Porto AlegrePorto AlegreBrazil
  2. 2.Infectious Disease Service, Hospital de Clínicas de Porto AlegrePorto AlegreBrazil
  3. 3.Hospital Infection Control Committee, Hospital de Clínicas de Porto AlegrePorto AlegreBrazil

Personalised recommendations